Okuma HS, Watanabe K, Tsuchihashi K, Machida R, et al. Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial). Clin Cancer Res 2023;29:5079-5086.
PMID: 37819940